Heart Drug Trial Finds Prasugrel and Ticagrelor Perform Similarly in Acute Coronary Syndromes

The SWITCH-SWEDEHEART trial, presented at the ESC Congress and published by the New England Journal of Medicine (@NEJM), compared prasugrel and ticagrelor — two drugs that stop blood platelets from clumping together (antiplatelet medicines) — in patients being treated for acute coronary syndromes (ACS), the umbrella term for heart attacks and unstable angina. The trial found the two drugs performed at a comparable level across the primary outcomes measured. However, the trial did find a difference in one secondary measure: patients on prasugrel experienced lower rates of major bleeding compared with those on ticagrelor — a finding that may influence prescribing decisions for patients at higher bleeding risk.

The findings matter because both drugs are already in routine use across NHS cardiology services, including those serving Kent and Medway. When two treatments show similar results, clinicians and health systems can factor in cost, individual patient tolerance and local formulary decisions — and that kind of evidence is exactly what treatment policy trials are designed to produce.

An accompanying editorial in the same journal addressed the broader question of how trials like SWITCH-SWEDEHEART fit into clinical practice. The editorial discussed the emerging role of what researchers call treatment policy implementation trials — studies designed not just to test whether a drug works, but to help hospitals and health systems decide how to apply that evidence at scale.

The trial was presented at ESC Congress, the annual meeting of the European Society of Cardiology (@escardio), one of the main forums where cardiology research is shared with clinicians internationally.

If you have concerns about heart symptoms — including chest pain, breathlessness or an irregular heartbeat — contact your GP or call NHS 111. In an emergency, call 999.